Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clinical trials (Phase I, II, or I/II) evaluating the infusion of engineered NK cell therapies in hematological or solid tumor patients were registered on ClinicalTrials.gov until 31–12–2021. Studies are sorted by NK cell source (PB-NK, UCB-NK, iPSCs, NK-92, Unknown). The type of engineered NK products (scFv-CAR-NK, Receptor-CAR-NK, CD16-engineered, or CD16- and scFv-engineered CAR-NK), the engineering method, transgene structure, and the clinical trial design and outcome (when available) are presented. Trial status is updated to August 2022. PB: peripheral blood; UCB: umbilical cord blood; iPSCs: induced pluripotent stem cells; scFv: single-chain variable fragment.